MDA 2025: Digital monitoring tool for myasthenia gravis found feasible

Inebilizumab eases gMG symptoms in anti-AChR antibody patients

One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…

How I navigate fun days without crashing due to MG

Seventeen years of living with myasthenia gravis (MG) has made me a pro at navigating daily life. I’ve learned how to handle both routine tasks and high-pressure days because being sick doesn’t mean I get to sit out on life. Over the years, I’ve worked on big projects, organized…

Myasthenia gravis requires us to play the long game

It wasn’t my intention to write a column about exhaustion, fatigue, and the part they play in my life with myasthenia gravis (MG). But here’s what happened. I woke up yesterday and went about my usual routine. I ate breakfast, showered, shaved, and dressed. Then I sat at my…

MDA 2025: Responses to Zilbrysq now at over 2 years in RAISE-XT

More than two years of treatment with Zilbrysq (zilucoplan) continues to be associated with sustained clinical responses in adults with generalized myasthenia gravis (gMG), according to interim analyses of the long-term Phase 3 RAISE-XT extension study. These new findings, consistent with earlier interim trial analyses, were presented…